Vertex Pharmaceuticals (VRTX) Non-Current Debt (2009 - 2016)

Vertex Pharmaceuticals' Non-Current Debt history runs 5 years deep, the most recent figure standing at $74.9 million for Q2 2016.

• In Q2 2016, Non-Current Debt fell 70.26% year-over-year to $74.9 million; the TTM figure through Jun 2016 stood at $74.9 million (down 70.26% YoY), while the FY2015 annual figure was $223.9 million, down 20.21% from the prior year.
• Non-Current Debt was $74.9 million for Q2 2016 at Vertex Pharmaceuticals, down from $149.6 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $294.8 million in Q3 2015 to a low of $74.9 million in Q2 2016.
• Historically, Non-Current Debt has averaged $229.6 million across 3 years, with a median of $259.1 million in 2015.
• The sharpest annual moves came in 2015 and 2016: Non-Current Debt grew 0.03% in 2015, then tumbled 70.26% in 2016.
• A 3-year view of Non-Current Debt shows it stood at $280.6 million in 2014, then retreated by 20.21% to $223.9 million in 2015, then sank by 66.53% to $74.9 million in 2016.
• The last three Non-Current Debt figures came in at $74.9 million (Q2 2016), $149.6 million (Q1 2016), and $223.9 million (Q4 2015), per Business Quant data.